Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 5/20 | 0.62 |
| ▸ | EGLN1 | Q9GZT9 | 11/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.34 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3522129 | 0.83 | EGLN3 (0.67) | EGLN3EGLN1FTOEGLN2KDM5B | |
| SCHEMBL3524985 | 0.83 | EGLN3 (0.40) | EGLN3EGLN1 | |
| SCHEMBL3763287 | 0.81 | EGLN3 (0.70) | EGLN3EGLN1FTOEGLN2KDM5B | |
| SCHEMBL3522213 | 0.80 | EGLN3 (0.83) | EGLN3EGLN1FTOEGLN2KDM5B | |
| SCHEMBL3757210 | 0.79 | EGLN3 (0.78) | EGLN3EGLN1FTOEGLN2KDM5B | |
| SCHEMBL3758545 | 0.79 | EGLN3 (0.74) | EGLN3EGLN1FTOEGLN2KDM5B | |
| SCHEMBL3766921 | 0.78 | EGLN3 (0.69) | EGLN3EGLN1FTOEGLN2KDM5B | |
| SCHEMBL3748507 | 0.78 | EGLN3 (0.80) | EGLN3EGLN1FTOEGLN2 | |
| SCHEMBL3522363 | 0.78 | EGLN3 (0.69) | EGLN3EGLN1FTOEGLN2 | |
| SCHEMBL3536925 | 0.77 | EGLN3 (0.62) | EGLN3EGLN1FTOEGLN2KDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-12-02 | — | — | US | claimed |
| EP-2227770-A2 | PROLYL HYDROXYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-09-15 | — | — | EP | claimed |
| WO-2009073497-A2 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-11 | — | — | WO | claimed |
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-12-02 | — | — | US | disclosed |
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-12-02 | — | — | US | disclosed |
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-12-02 | — | — | US | disclosed |
| WO-2009073497-A2 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | EGLN3 2/4885EGLN1 6/4885APEX1 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.